100 Recruiting Studies Using Capecitabine
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Capecitabine
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
Pancreatic Adenocarcinoma
View Study & Checklist ➔Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
📍 M D Anderson Cancer Center — Houston, Texas
Clinical Stage I Gastric Cancer AJCC v8
View Study & Checklist ➔Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
📍 University of Alabama at Birmingham-Medicine ( Site 0065) — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
📍 University of California, Irvine — Irvine, California
Rectal Cancer
View Study & Checklist ➔Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Borderline Ovarian Mucinous Tumor
View Study & Checklist ➔Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
📍 University of Nebraska Medical Center — Omaha, Nebraska
Pancreatic Adenocarcinoma
View Study & Checklist ➔Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
📍 Research Site — Baltimore, Maryland
Gastric Cancer
View Study & Checklist ➔Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
📍 Zuckerberg San Francisco General Hospital — San Francisco, California
AIDS-Related Anal Carcinoma
View Study & Checklist ➔A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
📍 Research Site — Gilbert, Arizona
Breast Cancer
View Study & Checklist ➔Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
📍 Emory University — Atlanta, Georgia
Epstein-Barr Virus Positive
View Study & Checklist ➔A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
📍 Research Site — Duarte, California
Breast Cancer
View Study & Checklist ➔Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Pancreatic Cancer
View Study & Checklist ➔ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
📍 BRCR Medical Center Inc. — Plantation, Florida
HER2-positive Breast Cancer
View Study & Checklist ➔Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
📍 Kingman Regional Medical Center — Kingman, Arizona
Gastric Neuroendocrine Carcinoma
View Study & Checklist ➔Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Locally Advanced Rectal Carcinoma
View Study & Checklist ➔Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
📍 Moffitt Cancer Center — Tampa, Florida
Rectal Adenocarcinoma
View Study & Checklist ➔A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
📍 Research Site — Commack, New York
Metastatic Breast Cancer
View Study & Checklist ➔Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Colon Adenocarcinoma
View Study & Checklist ➔A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
📍 Research Site — Daphne, Alabama
Breast Cancer
View Study & Checklist ➔A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
📍 Mayo Clinic Hospital — Phoenix, Arizona
Neoplasms
View Study & Checklist ➔A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
📍 Research Site — Duarte, California
Breast Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
📍 Ironwood Cancer & Research Centers - Chandler II — Chandler, Arizona
Breast Cancer
View Study & Checklist ➔A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
📍 Summit Therapeutics Research Site — Los Angeles, California
Metastatic Colorectal Cancer
View Study & Checklist ➔Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
📍 Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
Locally Advanced or Unresectable Metastatic Breast Cancer
View Study & Checklist ➔A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
📍 Pacific Cancer Care — Monterey, California
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
View Study & Checklist ➔Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
📍 Washington University School of Medicine — St Louis, Missouri
Carcinoma
View Study & Checklist ➔Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
📍 Sibley Memorial Hospital — Washington D.C., District of Columbia
Triple Negative Breast Cancer
View Study & Checklist ➔Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
📍 Research Site — Birmingham, Alabama
Biliary Tract Cancer
View Study & Checklist ➔An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
📍 UCLA Healthcare Hematology-Oncology — Santa Monica, California
Pancreatic Cancer
View Study & Checklist ➔A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
📍 Hospital de Gastroenterología Dr Bonorino Udaondo — Buenos Aires,
Gastric Neoplasms
View Study & Checklist ➔Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
📍 Research Site — Scottsdale, Arizona
Advanced or Metastatic Breast Cancer
View Study & Checklist ➔Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Clinical Stage I Esophageal Adenocarcinoma AJCC v8
View Study & Checklist ➔A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
📍 Research Site — Los Angeles, California
Advanced Upper Gastrointestinal Tract Adenocarcinoma
View Study & Checklist ➔Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Anal Basaloid Carcinoma
View Study & Checklist ➔Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
📍 Mayo Clinic Hospital — Phoenix, Arizona
Colorectal Carcinoma
View Study & Checklist ➔A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
📍 HonorHealth Research Institute — Scottsdale, Arizona
Metastatic Pancreatic Adenocarcinoma
View Study & Checklist ➔Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
📍 California Cancer Associates for Research & Excellence, Inc. — Encinitas, California
Colorectal Cancer
View Study & Checklist ➔Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
📍 Fairbanks Memorial Hospital — Fairbanks, Alaska
Metastatic Pancreatic Neuroendocrine Tumor
View Study & Checklist ➔REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
📍 University of Cincinnati Medical Center — Cincinnati, Ohio
Anal Cancer
View Study & Checklist ➔A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
📍 Local Institution - 0003 — Tucson, Arizona
Advanced Solid Tumors
View Study & Checklist ➔Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
📍 Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Metastatic Pancreatic Cancer
View Study & Checklist ➔Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
📍 Mobile Infirmary Medical Center — Mobile, Alabama
Estrogen Receptor Negative
View Study & Checklist ➔Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
📍 Kaiser Permanente Dublin — Dublin, California
Clinical Stage I Gastric Cancer AJCC v8
View Study & Checklist ➔Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
View Study & Checklist ➔Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
📍 Cedars-Sinai Medical Center — Los Angeles, California
Triple Negative Breast Cancer
View Study & Checklist ➔Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
📍 Hartford Healthcare Cancer Institute @ Hartford Hospital — Hartford, Connecticut
Breast Cancer
View Study & Checklist ➔A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
📍 Research Site 1141-0 — Tucson, Arizona
Metastatic Breast Cancer
View Study & Checklist ➔Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
📍 Kaiser Anaheim Medical Center — Anaheim, California
Gastrinoma
View Study & Checklist ➔ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
📍 Providence Cancer Center — Portland, Oregon
Rectal Adenocarcinoma
View Study & Checklist ➔A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
📍 UCLA Medical Center — Los Angeles, California
Breast Cancer
View Study & Checklist ➔Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
📍 Johns Hopkins SKCCC — Baltimore, Maryland
Rectal Cancer
View Study & Checklist ➔A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
📍 Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona
Breast Neoplasms
View Study & Checklist ➔Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
📍 Hartford Healthcare (Data Collection) — Hartford, Connecticut
Rectal Adenocarcinoma
View Study & Checklist ➔A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
📍 Helios Clinical Research — Cerritos, California
Advanced Unresectable Gastric Adenocarcinoma
View Study & Checklist ➔Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
Rectal Cancer
View Study & Checklist ➔A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
📍 University of Florida Proton Therapy Institute — Jacksonville, Florida
Pancreatic Cancer
View Study & Checklist ➔Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
📍 Research Site — Mobile, Alabama
Gastric Cancer
View Study & Checklist ➔Pan Tumor Rollover Study
📍 Local Institution - 0220 — Huntsville, Alabama
Cancer
View Study & Checklist ➔Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)
📍 McGill University Health Centre — Montreal, Quebec
Colorectal Carcinoma
View Study & Checklist ➔PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
📍 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Triple Negative Breast Cancer
View Study & Checklist ➔Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
📍 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Colorectal Cancer
View Study & Checklist ➔A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
📍 Southern Cancer Center (SCC) ( Site 8000) — Daphne, Alabama
Breast Neoplasms
View Study & Checklist ➔Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Malignant Digestive System Neoplasm
View Study & Checklist ➔Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
📍 University of Virginia — Charlottesville, Virginia
Breast Cancer
View Study & Checklist ➔Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist ➔PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Estrogen-receptor-positive Breast Cancer
View Study & Checklist ➔NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
📍 University of Southern California — Los Angeles, California
Locally Advanced Rectal Cancer (LARC)
View Study & Checklist ➔A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Biliary Cancer
View Study & Checklist ➔A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
📍 Massachusetts General Hospital (Data Collection Only) — Boston, Massachusetts
Esophageal Cancer
View Study & Checklist ➔A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
📍 University of California Irvine Medical Center — Orange, California
Gastric Adenocarcinoma
View Study & Checklist ➔Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
📍 The Oncology Institute of Hope and Innovation — Cerritos, California
Metastatic Breast Cancer
View Study & Checklist ➔A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
📍 Pan American Center for Oncology Trials — Dorado,
Gastric Adenocarcinoma
View Study & Checklist ➔A Study of Tetrathiomolybdate (TM) Plus Capecitabine
📍 Indiana University Simon Cancer Center — Indianapolis, Indiana
Triple Negative Breast Cancer
View Study & Checklist ➔Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
Locally Advanced Malignant Solid Neoplasm
View Study & Checklist ➔A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
📍 Los Angeles General Medical Center — Los Angeles, California
Breast
View Study & Checklist ➔Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
📍 Alabama Oncology — Birmingham, Alabama
Triple Negative Breast Cancer
View Study & Checklist ➔Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Locally Advanced Rectal Carcinoma
View Study & Checklist ➔SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
📍 University of Miami — Miami, Florida
Locally Advanced Rectal Cancer
View Study & Checklist ➔MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Rectal Adenocarcinoma
View Study & Checklist ➔A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
📍 Research Site — Newark, Delaware
Gastroesophageal Adenocarcinoma
View Study & Checklist ➔Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
📍 I-Mab Site 1016 — Goodyear, Arizona
Solid Tumor
View Study & Checklist ➔Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
📍 The Ottawa Hospital — Ottawa, Ontario
HER2-positive Breast Cancer
View Study & Checklist ➔A Study of DB-1310 in Advanced/Metastatic Solid Tumors
📍 University of California, Davis Comprehensive Cancer Center — Sacramento, California
Advanced Solid Tumor
View Study & Checklist ➔Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
📍 START Midwest — Grand Rapids, Michigan
Triple Negative Breast Cancer (TNBC)
View Study & Checklist ➔Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
📍 Research Site — Los Angeles, California
Gastric Cancer
View Study & Checklist ➔Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
📍 UCLA Hematology/Oncology - Parkside ( Site 0021) — Santa Monica, California
Breast Neoplasms
View Study & Checklist ➔ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
📍 M D Anderson Cancer Center — Houston, Texas
Liver Metastases
View Study & Checklist ➔A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
📍 Arizona Oncology Associates — Tucson, Arizona
Breast Cancer
View Study & Checklist ➔Adaptive Radiation in Anal Cancer
📍 Columbia University Irving Medical Center — New York, New York
Anal Squamous Cell Carcinoma
View Study & Checklist ➔Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
📍 Infirmary Cancer Care ( Site 0001) — Mobile, Alabama
Triple-Negative Breast Cancer
View Study & Checklist ➔A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
📍 START Los Angeles, LLC — Los Angeles, California
Advanced Solid Tumors
View Study & Checklist ➔A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
📍 Research Site — Anchorage, Alaska
HER2-positive Gastric Cancer
View Study & Checklist ➔CapTemY90 for Grade 2/3 NET Liver Metastases
📍 UC San Diego — La Jolla, California
Neuroendocrine Tumor Grade 2
View Study & Checklist ➔RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
📍 The West Clinic, PC dba West Cancer Center — Germantown, Tennessee
HER2-positive Breast Cancer
View Study & Checklist ➔D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
📍 The University of Arizona Cancer Center — Tucson, Arizona
Biliary Tract Cancer (BTC)
View Study & Checklist ➔Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
📍 University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) — Tucson, Arizona
Gastroesophageal Junction
View Study & Checklist ➔Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
📍 University of Alabama Birmingham — Birmingham, Alabama
Invasive Mammary Carcinoma
View Study & Checklist ➔Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
📍 Henry Ford Cancer-Detroit — Detroit, Michigan
Gastrointestinal Cancer
View Study & Checklist ➔A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔